The effect of carbimazole on thyroid autoantibody synthesis by thyroid lymphocytes.
Thyroid autoantibody synthesis was investigated in cultures of lymphocytes isolated from several sources, including thyroid and lymph nodes from patients with hyperthyroid Graves' disease treated preoperatively with carbimazole or propranolol. The ability of thyroid lymphocytes to secrete immunoglobulins, including thyroid microsomal or thyroglobulin autoantibodies, was markedly reduced in lymphocyte suspensions obtained from patients treated with carbimazole compared with suspensions from patients treated with propranolol. This effect (which was greater in individuals treated with carbimazole for longer periods) was attributable to a significant reduction in the number of viable lymphocytes present after the 14-day culture interval. In contrast, the type of preoperative therapy had little effect on cultures of lymphocytes obtained from lymph nodes draining the thyroid. Although it is not yet clear whether carbimazole exerts its effects in vivo by direct immunosuppression or indirectly by altering the thyroid microenvironment, our observations indicate that the fall in serum levels of thyroid autoantibodies that occurs during carbimazole therapy is related to an effect of the drug on lymphocytes within the thyroid.
D000917:Antibody Formation / Q000187:drug effects*; D001323:Autoantibodies / Q000096:biosynthesis*; D002231:Carbimazole / Q000494:pharmacology*; D002478:Cells, Cultured; D006111:Graves Disease / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D011433:Propranolol / Q000494:pharmacology; D013961:Thyroid Gland / Q000276:immunology*
D001323:Autoantibodies; D002231:Carbimazole; D011433:Propranolol